

Palbociclib efficacious in metastatic breast cancer

17 November 2016



[women](#) in this study—was neutropenia.

"Among patients with previously untreated ER-positive, HER2-negative advanced breast cancer, palbociclib combined with letrozole resulted in significantly longer progression-free survival than that with letrozole alone, although the rates of myelotoxic effects were higher with palbociclib-letrozole," the authors conclude.

The study was funded by Pfizer, the manufacturer of palbociclib.

More information: [Full Text \(subscription or payment may be required\)](#)
[Editorial \(subscription or payment may be required\)](#)

Copyright © 2016 [HealthDay](#). All rights reserved.

(HealthDay)—Palbociclib can help slow the progression of advanced breast cancer, according to a study published in the Nov. 17 issue of the *New England Journal of Medicine*.

Richard Finn, M.D., an assistant professor of medicine at the University of California, Los Angeles, and colleagues tested palbociclib-letrozole as a first-line treatment for estrogen-receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative [advanced breast cancer](#). They randomly assigned 666 women to receive the [drug combination](#) or letrozole alone, and followed them for up to three years.

At that point, the researchers found that 43.7 percent of women in the palbociclib group had either died or seen their cancer progress. That compared with 61.7 percent of women on letrozole alone. Women on the drug combination typically remained progression-free for 24.8 months, versus 14.5 months for women on letrozole. One of the most common side effects—seen in two-thirds of

APA citation: Palbociclib efficacious in metastatic breast cancer (2016, November 17) retrieved 27 April 2021 from <https://medicalxpress.com/news/2016-11-palbociclib-efficacious-metastatic-breast-cancer.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.